Form 4: Beta Bionics CFO Exercises Options, Sells Shares
Insider Transaction Report
Beta Bionics' Chief Financial Officer, Stephen Feider, executed a planned sale of 9,900 shares following the exercise of stock options.
Summary
- Stephen Feider, Chief Financial Officer of Beta Bionics, Inc. (BBNX), reported transactions on September 8, 2025.
- Feider exercised employee stock options to acquire 9,900 shares of common stock at an exercise price of $5.10 per share.
- Concurrently, Feider sold 9,900 shares of common stock at a weighted average price of $21.1264 per share.
- The sale was conducted pursuant to a Rule 10b5-1 trading plan, which was adopted on May 15, 2025.
- Following these transactions, Feider directly beneficially owns 44,041 shares of common stock and 89,695 employee stock options.
Sentiment
Score: 5
Explanation: Neutral. This is a routine insider transaction (option exercise and sale) under a pre-arranged 10b5-1 plan, which is a common liquidity event for executives and does not inherently signal positive or negative company performance.
Positives
- The transaction was executed under a pre-arranged Rule 10b5-1 plan, indicating a planned liquidity event rather than a reaction to new, non-public information.
- The exercise of options and subsequent sale demonstrates the CFO's ability to realize value from long-term equity compensation.
Negatives
- An insider sale, even under a 10b5-1 plan, can sometimes be perceived negatively by investors, though the impact is often mitigated by the pre-planned nature.
Future Outlook
The filing does not contain forward-looking statements or guidance regarding the company's future performance or outlook.
Industry Context
This filing is a routine insider transaction report and does not provide specific insights into broader industry trends or competitive landscape. It reflects an individual executive's personal financial planning.
Related Party Transactions
- The sale of shares was executed pursuant to a Rule 10b5-1 Plan adopted by Stephen Feider, an officer of Beta Bionics, Inc., on May 15, 2025. This plan allows insiders to pre-arrange sales of company stock to avoid accusations of trading on material non-public information.
Stakeholder Impact
- Shareholders: The sale represents a minor dilution of ownership if the shares were newly issued upon exercise, but primarily reflects an executive's personal financial management. The pre-planned nature mitigates concerns about insider sentiment.
- Employees: No direct impact on employees is indicated by this filing.
Key Dates
| Date | Description |
|---|---|
| 09/14/2023 | Start date for the 48 equal monthly installments vesting schedule of the employee stock option. |
| 05/15/2025 | Date the Rule 10b5-1 Plan was adopted by Stephen Feider. |
| 09/08/2025 | Date of the reported option exercise and subsequent sale transactions. |
| 09/09/2025 | Date the Form 4 filing was signed. |
| 09/13/2033 | Expiration date of the employee stock option. |
Keywords
Beta Bionics, BBNX, Form 4, Insider Trading, Stock Options, Rule 10b5-1 Plan, CFO, Equity Compensation, Share Sale
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.